MBsNRP2-based ultrasound molecular imaging for early diagnosis of castration-resistant prostate cancer
Regarding the progression of prostate cancer, the expression of NRP2 on neovascular endothelial cells gradually increases, potentially serving as a molecular target for early diagnosis of CRPC. The attached MBs<sub>NRP2</sub> intensity has significant differences in prostate cancer models at different stages. These findings suggest that ultrasound contrast imaging based on MBs<sub>NRP2</sub> could be a novel strategy for the early diagnosis of CRPC.
Authors
- Jiaqi Gong (ORCID: https://orcid.org/0000-0001-9694-2518)
- Yujie Wan (ORCID: https://orcid.org/0000-0003-3121-3386)
- Jia Tang (ORCID: https://orcid.org/0000-0003-3977-6706)
- Xinzhi Xu (ORCID: https://orcid.org/0000-0002-7054-1406)
- Ruixia Hong
- Fang Li (ORCID: https://orcid.org/0000-0002-7551-5899)
- Yongchun Zhong (ORCID: https://orcid.org/0000-0001-9919-1430)
- Hang Zhou (ORCID: https://orcid.org/0000-0001-6270-8424)
- Qizhi Wang (ORCID: https://orcid.org/0009-0003-3360-5815)
- Na Wang (ORCID: https://orcid.org/0000-0002-8314-9972)
Institutions
- Chongqing University (CN)
- Chongqing Cancer Hospital (CN)
Publication Details
- Journal
- BMC Cancer
- Published
- 2025-04-24
- DOI
- https://doi.org/10.1186/s12885-025-14143-7
- Citations
- 2
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 3.04
Funders
- China Postdoctoral Science Foundation
- Fundamental Research Funds for the Central Universities